Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2025 Apr 15:2025.01.01.631020.
doi: 10.1101/2025.01.01.631020.

Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases

Affiliations
Free PMC article

Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases

Joel Finney et al. bioRxiv. .
Free PMC article

Update in

Abstract

The discovery of broadly protective antibodies to the influenza virus neuraminidase (NA) has raised interest in NA as a vaccine target. However, recombinant, solubilized tetrameric NA ectodomains are often challenging to express and isolate, hindering the study of anti-NA humoral responses. To address this obstacle, we established a panel of 22 non-adherent cell lines stably expressing native, historical N1, N2, N3, N9, and NB NAs anchored on the cell surface. The cell lines are barcoded with fluorescent proteins, enabling high-throughput, 16-plex analyses of antibody binding with commonly available flow cytometers. The cell lines were at least as efficient as a Luminex multiplex binding assay at identifying NA antibodies from a library of unselected clonal IgGs derived from human memory B cells. The cell lines were also useful for measuring the magnitude and breadth of the serum antibody response elicited by experimental infection of rhesus macaques with influenza virus. The membrane-anchored NAs are catalytically active and are compatible with established sialidase activity assays. NA-expressing K530 cell lines therefore represent a useful tool for studying NA immunity and evaluating influenza vaccine efficacy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interests EBW has received research funding from Pfizer, Moderna, Seqirus, Najit Technologies, and Clinetic for the conduct of clinical research studies. He has also received support as an advisor to Vaxcyte and Pfizer, as a consultant to ILiAD Biotechnologies, and as DSMB member for Shionogi. The other authors have no competing interests to declare.

Publication types

LinkOut - more resources